Drug intelligence / Profile preview

APS009

Development stage: Preclinical
Lead developer: Applied Pharmaceutical Science
Modality: Small Molecules
Administration: Inhalation, Subcutaneous

Overview

APS009 is a small molecule drug candidate under development by Applied Pharmaceutical Science, Inc., designed for the treatment of multiple solid tumors. The therapeutic strategy for APS009 is based on the concept of synthetic lethality, a mechanism where the inhibition of a specific target results in cell death only in cells with particular genetic deficiencies, such as those found in cancer. Currently in the lead discovery phase of development, the specific molecular target and mechanism of action for APS009 remain proprietary and have not been disclosed by the company.

Beyond the preview

Go deeper on APS009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APS009.

Explore the full profile